期刊
CELL REPORTS PHYSICAL SCIENCE
卷 3, 期 10, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xcrp.2022.101062
关键词
-
类别
资金
- National Key R&D Program of China [2021YFA1101000]
- Zhejiang Provincial Natural Science Foundation of China [LD22H300003]
- National Natural Science Foundation of China [82272637, 82204429]
This review focuses on the discovery and development of orally available anti-cancer PROTAC degraders, summarizing the strategies applied to this end, which may provide a reference for the future discovery of new oral-available PROTAC degraders for the treatment of various human diseases.
In the past two decades, we have witnessed the discovery and development of many potent and efficacious proteolysis-targeting chimera (PROTAC) degraders, with several in phase I/II clinical trials. However, achieving good oral bioavailability for these degraders remains one of the biggest challenges, given the fact that PROTACs are often beyond rule of 5'' for small-molecule drugs because of their higher molecular weight and other poor physiochemical properties. In this review, we focus on the current efforts in the discovery and development of various orally available anti-cancer PROTAC degraders, and comprehensively summarize the strategies applied to this end. We believe that the strategies summarized here may provide a reference for future discovery of new oral-available PROTAC degraders for the treatment of various human diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据